Analysts at Credit Suisse Group initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report issued to clients and investors on Monday, The Fly reports. The brokerage set a “neutral” rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the company. ValuEngine downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 13th. Cantor Fitzgerald decreased their target price on Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating on the stock in a research note on Monday, May 13th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating on the stock in a research note on Wednesday, May 8th. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 8th. Finally, Canaccord Genuity reissued a “hold” rating and set a $353.00 target price (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, May 8th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $404.88.

Shares of REGN stock traded down $2.37 during trading hours on Monday, reaching $302.57. 653,295 shares of the company traded hands, compared to its average volume of 784,839. Regeneron Pharmaceuticals has a 12-month low of $291.10 and a 12-month high of $442.00. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08. The stock has a market cap of $33.06 billion, a P/E ratio of 15.28, a PEG ratio of 1.44 and a beta of 1.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The company had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.76 billion. During the same period in the previous year, the firm earned $4.67 earnings per share. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals will post 18.37 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total value of $305,930.00. Following the sale, the director now owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The disclosure for this sale can be found here. In the last ninety days, insiders sold 141,968 shares of company stock worth $57,360,056. Corporate insiders own 11.84% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allstate Corp increased its position in shares of Regeneron Pharmaceuticals by 11.6% during the 1st quarter. Allstate Corp now owns 5,742 shares of the biopharmaceutical company’s stock valued at $2,358,000 after purchasing an additional 595 shares during the last quarter. Columbia Asset Management increased its position in shares of Regeneron Pharmaceuticals by 63.9% during the 1st quarter. Columbia Asset Management now owns 795 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 310 shares during the last quarter. Advisory Services Network LLC increased its position in shares of Regeneron Pharmaceuticals by 393.0% during the 1st quarter. Advisory Services Network LLC now owns 4,407 shares of the biopharmaceutical company’s stock valued at $1,809,000 after purchasing an additional 3,513 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 217.6% during the 1st quarter. Nordea Investment Management AB now owns 13,386 shares of the biopharmaceutical company’s stock valued at $5,494,000 after purchasing an additional 9,171 shares during the last quarter. Finally, Horizon Investments LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $206,000. 67.63% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Quiet Period Expirations

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.